Home / Letter From The Editor / July 19, 2018

July 19, 2018

Jul 19, 2018
 

Many of our patients use basal insulin with few hypoglycemic problems. Even at large doses the risk of hypoglycemia is small in most of our type 2 insulin using patients. The problem comes when the patient is not adequately controlled and we decide to use mealtime insulin to get them closer to goal.

The use of mealtime insulin requires more than just dialing up a number on a pen and injecting. It definitely requires the patient to check their glucose more often, something that most of these patients are unwilling to do. This lack of monitoring is what usually leads to bouts of hypoglycemia in patients.

So what is a possible solution? Our Pharm.D. Candidate Kaytie A. Weierstahl, from the LECOM School of Pharmacy, has taken a look at the use of an SGLT-2 inhibitor, as an add on to these high dose insulin patients and the results she has found have a lead role in this month’s SGLT-2 Therapy Special Edition.

Click here to see what she found out.

Dave Joffe

Editor-in-chief